anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
tFUS is an emerging neuromodulatory tool that uses pulses of low-intensity acoustic waves to stimulate deep brain structures such as the thalamus. tFUS has recently been used to probe deep brain structures in unresponsive wakefulness, pain, anxiety, and other neuropsychiatric conditions. However, tFUS is restricted mainly by use in the MR scanner environment, thus limiting session numbers by scan cost and participant comfort. Furthermore, with few human studies to date, the parameter space and mechanisms of action warrant further elucidation. Using novel focused ultrasound methods, investigators can stimulate at a minimum penetration distance of 20mm, uniquely enabling the study of the neuromodulatory effects of tFUS on cortical tissue. Specifically, investigators propose to study the effects of motor tFUS on motor-evoked potentials (MEPs) and GABA concentration. The proposed research is critical for understanding tFUS and advancing its therapeutic potential for future clinical trials.
1-(tert. butylamino) -3-((-chloro m-tolyl)oxy)-2-propanol (I) can be used in a transdermal application form to reduce the concn. of total cholesterol in mammals. It also increases the concn. of high density lipoproteins, reduces the concn. of low density lipoproteins and reduces the concn. of triglycerides. USE/ADVANTAGE - (I) reduces blood lipid levels and can be used in transdermal application forms to treat atherosilerosis. (I) is a non-selective beta-receptor blocker without intrinsic sympathomimetic activity. In an example, a plaster was prepd. according to example 4 of EP0186019. The (I) plaster consisted of a matrix system consisting of a multilayered polyisobutylene contact film of total thickness 0.1mm which had been impregnated with the pharmaceutical. The outside was covered with a polyester foil. A plaster of 25 cm2 and 30 mg (I) in the form of the free base. The active surface was protected by a siliconised and metallised polyester foil which was removed before application
Low-FODMAPdiet intervention as group treatment in three steps during 12 weeks, elimination, re-introduction and personalization of the diet. This group of participants starts immediate.
Purpose: The purpose of this study was to provide a systematic review and, where possible, meta-analysis on the prevalence of physical health conditions in sexual minority men (SMM, i.e., gay- and bisexual-identified men) compared with heterosexual-identified men. Methods: A systematic literature search in the databases MEDLINE, Embase, CENTRAL, CINAHL, and Web of Science was conducted on epidemiological studies on physical health conditions, classified in the Global Burden of Disease project and published between 2000 and 2021. Meta-analyses comparing odds ratios were calculated. Results: In total, 23,649 abstracts were screened, and 32 studies were included in the systematic review. Main findings were that (1) Largest differences in prevalence by sexual identity were found for chronic respiratory diseases, particularly asthma: overall, SMM were significantly almost 50% more likely to suffer from asthma than heterosexual men. (2) Evidence of higher prevalence was also found for chronic kidney diseases and headache disorders in gay men and for hepatitis B/C in both gay and bisexual men. (3) We found an overall trend that bisexual men were more affected by some of the physical health conditions compared with gay men (e.g., cardiovascular diseases, asthma). However, regarding cancer, headache disorders, and hepatitis, gay men were more affected. Conclusion: We found evidence of physical health disparities by sexual identity, suggesting more health issues in SMM. Since some of these findings rely on few comparisons or small samples of SMM only, this review is intended to be a vehement plea for routinely including sexual identity assessment in health research and clinical practice.
Epithelial-mesenchymal transition (EMT) is a critical process for cancer progression, which is crucial in inhibiting the immunity in tumors and further boosting tumor metastasis. The suppression of EMT represents a promising strategy for inhibiting metastatic tumors. Herein, a series of new canadine platinum(IV) conjugates with potent antiproliferative and antimetastatic activities were developed, which activated by suppressing EMT and provoking immune response in tumors besides causing DNA injury. The complexes could covalently conjugate to DNA and induce mitochondria-mediated apoptosis via Bcl-2/Bax/caspase3 signaling. The EMT process was remarkably inhibited by suppressing the Wnt/β-catenin pathway, reversing the inflammatory tumor microenvironment, and inhibiting the HIF-1α pathway, which further resulted in the inhibited angiogenesis in tumors. Moreover, the antitumor immunity was elevated by blocking immune checkpoints PD-L1 and CD47 accompanied by the improvement of CD3+ and CD8+ T lymphocytes and the macrophage polarization from M2- toward M1-type simultaneously in tumors.
Disclosed are a Ruimailing concentrated pill and a preparation method thereof, which relate to the technical field of medicine and preparation method thereof. The Ruimailing concentrated pill consists of the following raw materials: prepared rehmannia root, Chinese magnoliavine fruit, barbary wolfberry fruit, twotooth achyranthes root, Indian buead, prepared tuber fleeceflower root, white paeony root, platycladi seed, thinleaf milkwort root-bark, roasted astragalus root, tangerine peel, epimedium herb, Chinese angelica, szechuan lovage rhizome, danshen root, ginseng, honey and water. The preparation method of the Ruimailing concentrated pill can be used for preparing the Ruimailing concentrated pill. The decoction or extract of all or part of the medicinal materials is mixed with appropriate adjuvant or fine powder of the medicinal materials and appropriate binder. The concentrated honeyed pill is prepared by using honey as a binder. The concentrated pill has small volume, high content of effective components, easy administration, and slow dissolution and absorption in vivo. The concentrated pill is suitable for various diseases such as chronic diseases.
Since recovery of virus-specific T cells is clearly associated with protection from infection with each of these viruses, adoptive immunotherapy to decrease the time to immune reconstitution is an attractive approach. Virus-specific T cells generated by repeated stimulation with antigen presenting cells (APCs) expressing viral antigens have been evaluated in clinical trials to prevent and treat viral infections in immunocompromised hosts. This approach eliminates alloreactive T cells.

To broaden the specificity of single CTL lines to include the three most common viral pathogens of stem cell recipients, investigators reactivated CMV and adenovirus-specific T cells by using mononuclear cells transduced with a recombinant adenoviral vector encoding the CMV antigen pp65 (Ad5f35CMVpp65). Subsequent stimulations with EBV-LCL transduced with the same vector both reactivated EBV-specific T cells and maintained the expansion of the activated adenovirus and CMV-specific T cells. This method reliably produced CTLs with cytotoxic function specific for all three viruses, which investigators infused into 14 stem cell recipients in a Phase I prophylaxis study. They observed recovery of immunity to CMV and EBV in all patients but an increase in adenovirus-specific T cells was only seen in patients who had evidence of adenovirus infection pre-infusion. A follow-up study in which the frequency of adenovirus-specific T cells was increased in the infused CTLs produced similar results, thus highlighting the importance of endogenous antigen to promote the expansion of infused T cells in vivo. Nevertheless, all patients in both clinical trials with pre-infusion CMV, adenovirus or EBV infection or reactivation were able to clear the infection, including one patient with severe adenoviral pneumonia requiring ventilatory support. CTLs recognizing multiple antigens can therefore produce clinically relevant effects against all three viruses.
Bivalirudin for injection contains bivalirudin which is a specific and reversible direct thrombin inhibitor. Bivalirudin is a synthetic, 20 amino acid peptide, with the chemical name of D-phenylalanyl-L-prolyl-L-arginyl-L-prolyl-glycyl-glycyl-glycyl-glycyl-L-asparagyl-glycyl-L-aspartyl-L-phenylalanyl-L-glutamyl-L-glutamyl-L-isoleucyl-L-prolyl-L-glutamyl-L-glutamyl-L-tyrosyl-L-leucine. The active pharmaceutical ingredient is in the form of bivalirudin trifluoroacetate as a white to off-white powder. The chemical name for bivalirudin trifluoroacetate is D-phenylalanyl-L-prolyl-L-arginyl-L-prolyl-glycyl-glycyl-glycyl-glycyl-L-asparagyl-glycyl-L-aspartyl-L-phenylalanyl-L-glutamyl-L-glutamyl-L-isoleucyl-L-prolyl-L-glutamyl-L-glutamyl-L-tyrosyl-L-leucine trifluoroacetate (Figure 1). The molecular weight of bivalirudin is 2180 daltons (anhydrous free base peptide).

Figure 1: Structural Formula for Bivalirudin Trifluoroacetate 

Bivalirudin for injection is supplied as a sterile white lyophilized cake, in single-dose vials. Each vial contains 250 mg bivalirudin, equivalent to an average of 275 mg of bivalirudin trifluoroacetate*, 125 mg mannitol, and sodium hydroxide to adjust the pH to 5-6 (equivalent of approximately 12.5 mg sodium). When reconstituted with Sterile Water for Injection, the product yields a clear to opalescent, colorless to slightly yellow solution, pH 5-6.  
*The range of bivalirudin trifluoroacetate is 270 mg to 280 mg based on a range of trifluoroacetic acid composition of 1.7 to 2.6 equivalents.
2-Amino benzimidazole derivs. of formula (I), in which R1 is H, methoxy or Cl, and R2 is H, F or NO2, are made by subjecting a cpd. of formula (II) to a cyclo-desulphurising process in which it is reacted with cupric oxide, opt. in presence of small amts. of sulphur and magnesium sulphate as dehydrating agent. The reaction is carried out in inert organic solvent such as chloroform or tetrahydrofurane.
The present invention relates generally to a technology platform, referred to as Phytologix™ for the discovery of novel bioactive pharmaceutical, nutraceutical and cosmetic agents. Specifically, this invention includes an integrated system for the collection of medicinal plants and creation of informatic databases related to these plants. This invention also relates to an improved standardized extraction and fractionation process, which provides significant advantages over the prior art in the terms of simplicity, efficiency of the separations, the quality of the library, low cost of the process and extraordinary throughput. This invention provides details to the structure dereplication process by utilizing the technology such as HPLC/PDA/MS coupled with high throughput bioassay data and an internal pure compound library. It has been proven to be much more efficient and accurate when compared to the prior art methods. Finally, the Phytologix™ platform has been approved as a realistic and efficient process by the demonstration of the whole process of discovery and development of natural COX-2 and tyrosinase inhibitors as novel nutraceutical and cosmetic products.
Advanced atherosclerosis is linked to plaque instability, which can result in rupture and the onset of a heart attack. Evidence gathered from human atheroma plaques indicates that intraplaque neovascularization poses a risk to plaque stability and may lead to plaque hemorrhage. Hence, targeting the neovascularization within the atheroma plaque has the potential to mitigate the plaque's vulnerability. While neovascularization has been extensively explored in the context of cancer, research on pharmacological inhibition of this phenomenon in atherosclerosis remains limited. This systematic review aimed to comprehensively assess current and emerging pharmacological interventions for inhibiting intraplaque neovascularization in preclinical settings. Electronic databases (Web of Science, PubMed, Scopus, and Ovid) were searched from January 2013 until February 1, 2024. Preclinical studies reporting the effect of any pharmacological interventions targeting intraplaque neovascularization were included. A total of 10 articles involving in vivo animal studies were eligible for inclusion, with five of them incorporating in vitro experiments to complement their in vivo findings. The pharmacological interventions studied were axitinib, ghrelin, K5, rosuvastatin, atorvastatin, 3PO, everolimus, melatonin, Si-Miao-Yong-A, and protocatechuic aldehyde. All the interventions showed a positive impact in inhibiting intraplaque neovascularization in various atherosclerotic animal models through various signaling pathways. This review provides valuable insights into pharmacological approaches to attenuate intraplaque neovascularization that could serve as a promising therapeutic avenue to enhance plaque stability.
The viral sepsis group comprises patients with sepsis secondary to viral infections, specifically COVID-19. Patients in this group were admitted to the ICU of Sichuan Provincial People's Hospital between July 2021 and December 2023 and diagnosed with viral sepsis based on positive RT-PCR results for SARS-CoV-2.
There is currently no uniform target for serum albumin levels in some pathological conditions, but recent studies have shown that serum albumin concentrations, disease severity, and mortality rates have been linked. Although the exact mechanism is unclear, serum albumin levels may have a protective effect on the potential antioxidant effect of maintaining physiological homeostasis and its anti-inflammatory effects. The indication and efficacy of parenteral albumin therapy in the care of patients in critical condition has long been a hot topic. Although previous mortality endpoint studies were negative, it is not certain that they can be used clearly in intensive care. According to earlier research, albumin is a very important circulating antioxidant. It is believed that early suplementattion of albumin may have a beneficial effect on oxidative stress and inflammation in septic patients.

The aim of our study is to investigate changes in parameters (inflammation, oxidative stress) that can be directly influenced by the administration of albumin in septic cases in need of intensive care. Also in our earlier, relatively small number of studies, chemiluminescence analysis of non-enzymatic total antioxidant capacity showed an increase in total antioxidant capacity in septic patients. The proposed study may also clarify the background of pathophysiological changes behind this phenomenon.
<P>PROBLEM TO BE SOLVED: To enable medical data to be efficiently shared by different medical facilities.  <P>SOLUTION: A shared server is configured of a controller 16 and a shared DB 17, and connected through a communication network to a plurality of medical facilities. A data registration part 41 registers medical data provided from each medical facility in a shared DB 17. The shared DB 17 manages the medical care data by management ID. The management ID is identification information for managing medical care data registered in the shared DB 17 by patient units, and assigned one by one to every patient. A data registration part 41 checks the registration circumstances of the past medical data of the same patient in the shared DB 17 in storing the accepted medical data, and when the medical data have already been registered, the data registration part 41 adds the medical care data to the management ID, and when the medical care data have not been registered, registers the medical care data by assigning new management ID thereto.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Participants in the experimental group will receive 5 weekly sessions of repetitive Transcranial Magnetic Stimulation (rTMS) for two weeks. An excitatory stimulation over the primary somatosensory area corresponding to the dominant hand will be applied. For this purpose, the motor area will be localized and a coil will be placed 2 cm posterior to it. An isolated pulse will be applied to the motor area to ensure that the coil is not placed over the motor area using 110% of the motor resting threshold. After this, 22 trains of 10 Hz at an intensity of 90% of the motor resting threshold will be applied for 4 seconds, with a rest between series of 10 seconds (a total of 880 pulses). After the stimulation, participants will train with the Forced Response training program for a total of 500 correct repetitions and the Purdue Pegboard Test with 4 repetitions for right hand, left hand and both hands.
AdipoRon (AR) can exert antidiabetic and anti-inflammatory effects by maintaining mitochondrial structure and function. The present study was designed to explore whether AR protects the auditory cells from cisplatin-induced damage and, if so, to probe the possible mechanisms underlying its action on this type of cells. Cell viability and apoptosis in House Ear Institute-Organization of Corti 1 (HEI-OC1 cells) and mouse cochlea hair cells (HCs) were detected by CCK8 and immunofluorescence. The expressions of apoptosis-related proteins (cleaved caspase-3 and Bcl-2), adiponectin receptor 1 (AdipoR 1) and the key factors relevant to mitochondrial biogenesis(SIRT1 and TFAM)were determined by Western blot and immunofluorescence. Changes in apoptotic rate and expression of SIRT1 and TFAM after silencing of AdipoR 1 (AdipoR 1-siRNA) in HEI-OC1 cells were measured by flow cytometry and Western blot. The levels of reactive oxygen species (ROS) were evaluated by MitoSox red staining. We found that 30 μM cisplatin exposure induced severe cellular damage, which resulted from activation of the mitochondrial apoptotic pathway. Cisplatin decreased the expression of AdipoR 1, SIRT1, and TFAM proteins, leading to impaired mitochondrial biogenesis and increased mitochondrial ROS production. 10 μM AR pre-treatment enhanced mitochondrial biogenesis, decreased mitochondrial ROS levels, alleviated imbalances in the mitochondrial apoptotic pathway, thus reducing cisplatin-induced apoptosis. Taken together, this work reveals that AR exerts anti-apoptotic effects, possibly via regulating mitochondrial biogenesis and function. Interestingly, AR might possess the promising potential to be a novel drug for the prevention and/ or treatment of cisplatin-induced ototoxicity.
FIELD: medicine, vaccine prophylaxis. SUBSTANCE: it is suggested to use capsule fraction 1 antigen F1 Y.pestis and, additionally, B-antigen isolated from cellular biomass of Y. Pseudotuberculosis. B-antigen is a large-molecular antigenic complex including polysaccharide, protein and lipid components. Primary immunization by said preparation could induce the development of pronounced specific insusceptibility to plague infection in white mice, guinea pigs, hamadryas baboons and is characterized by moderate post-vaccination reaction in experimental animals. EFFECT: higher efficiency of vaccine prophylaxis of plague. 1 cl, 3 ex, 5 tbl
The invention discloses a small ribonucleic acid interference molecule for specifically inhibiting an NK (Natural Killer) cell receptor KIR3DL1 and an application of the small ribonucleic acid interference molecule. The genbank login number of the mRNA of the targeted KIR3DL1 of the small ribonucleic acid interference molecule for specifically inhibiting the NK cell receptor KIR3DL1 is NM_013289. A large amount of experiments show that the siRNA fragment can remarkably inhibit the expression of the receptor KIR3DL1 of an NK cell membrane, and the siRNA subjected to various chemical modifications has the same effect of inhibiting the expression of the receptor KIR3DL1. The expression level of IFN-gamma and TNF-alpha cell factors in an NK cell can be remarkably increased after the expression of the receptor KIR3DL1 is inhibited. Meanwhile, the killing activity of the NK cell can be remarkably enhanced after the siRNA is transfected. Therefore, the small ribonucleic acid interference molecule for specifically inhibiting the NK cell receptor KIR3DL1 can be applied to preparation of anti-aids drugs.
The influenza virus (a germ) causes influenza or "flu." The flu is an infection of the breathing tubes and the lungs. In recent years, flu viruses that at first only infected birds have begun to infect humans. One of these strains is called avian influenza (A/H5N1 subtype) or "bird flu". Although no human cases of bird flu have been diagnosed in the United States, this strain has caused severe illness and death in several hundred people since late 2003. .

Vaccination is the most effective way of controlling flu and preventing its illness and complications. Vaccines help prevent illness by causing the body to make antibodies that fight infection. One way to improve the effectiveness of a vaccine is to include a substance that can stimulate the immune system to make more antibodies. This type of substance is called an adjuvant; one type of adjuvant is called AS03 (Adjuvant System 03).
INTRODUCTION: Colorectal injuries following traumas are significant causes of morbidity and mortality. This study aimed to evaluate the predictive effect of trauma scoring systems on mortality and morbidity in patients with post-traumatic colon injury.
METHODS: The records of 145 patients with colon trauma treated at Seyhan State Hospital between January 1, 2010, and January 1, 2020, were retrospectively analyzed. Injury Seriousness Score (ISS), Revised Trauma Score (RTS), Trauma Injury Severity Score (TRISS), and Colon Injury Score (CIS) scores were calculated for all patients. The predictive effects of scoring systems on primary outcomes of surgical treatment, complication rates, mortality, and anastomotic leaks were evaluated.
RESULTS: The mean age of the patients was 36.1 (SD ± 16.6), and the female/male ratio was 37/108. Anastomotic leakage occurred in 12 (8.2%) patients, and complications were observed in 57 (39.3%) patients. Seven (4.7%) patients died. A statistically significant relationship was observed between the increase in CIS and anastomotic leakage, morbidity, and mortality. Increases in ISS and decreases in RTS and TRISS were associated with increased morbidity and mortality, but these relationships were not statistically significant.
CONCLUSION: A significant relationship was observed between the increase in CIS and anastomotic leakage, morbidity, and mortality. The study suggests the need for a specific scoring system for evaluating the prognostic status in colon traumas, as ISS, RTS, and TRISS scores were not found to be significantly predictive of outcomes in this patient population.
POGZ (Pogo transposable element derived with ZNF domain) is known to function as a regulator of gene expression. While variations in the POGZ gene have been associated with intellectual disabilities and developmental delays in humans, the exact pathophysiological mechanisms remain unclear. To shed light on this, we created two lines of conditional knockout mice for Pogz, one specific to excitatory neurons (Emx1-Pogz mice) and the other to inhibitory neurons (Gad2-Pogz mice) in the brain. Emx1-Pogz mice showed a decrease in body weight, similar to total Pogz knockout mice. Although the two lines did not display significant morphological abnormalities in the telencephalon, impaired POGZ function affected the electrophysiological properties of both excitatory and inhibitory neurons differently. These findings suggest that these mouse lines could be useful tools for clarifying the precise pathophysiological mechanisms of neurodevelopmental disorders associated with POGZ gene abnormalities.